HIGHLIGHTS
- who: Yezhe Cheng et al. from the National Institutes of Health (NIH), United States have published the Article: Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132, in the Journal: (JOURNAL)
- what: The aim of this study was to improve the intratumoral accumulation of an antibody-drug conjugate (ADC) and minimize its off-target toxicity a novel anti-trophoblast antigen 2 (TROP2) ADC that was developed using 2-methylsulfonyl pyrimidine as the linker to conjugate its payload (KL610023) a belotecan-derivative topoisomerase I . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.